Receptor Agonist
Also known as: agonist
A receptor agonist is a molecule that binds a receptor and switches it on, producing a response the way the body's own signaling molecule does.
Receptors are proteins, usually on the cell surface, that change shape when the right molecule binds and then pass a signal into the cell. An agonist is any molecule that binds and activates that signal. Pharmacology describes an agonist with two separate properties: affinity, meaning how readily it binds, and efficacy, meaning how strong a response it produces once bound. Potency, usually reported as an EC50 (the concentration that produces half of the maximal effect), blends the two.
A full agonist can drive a system to its maximum response. A partial agonist produces a lower maximum even when every receptor is occupied, and when a full agonist is also present it can pull the overall response down. Most peptide drugs and research peptides are agonists: GLP-1 receptor agonists such as semaglutide, and ipamorelin at the growth hormone secretagogue (ghrelin) receptor. Newer molecules activate more than one receptor type from a single peptide chain.
Why it matters
Knowing a compound is an agonist tells you its limits. It can only turn up a pathway your body already has, so its effects and its side effects follow that receptor's biology. A GLP-1 receptor agonist, for example, acts on insulin and glucagon release, appetite, and stomach emptying because those are the jobs of that receptor.
Selectivity matters as much as strength. In the original animal pharmacology study, ipamorelin released growth hormone without raising ACTH or cortisol in pigs, while the older peptides GHRP-6 and GHRP-2 raised both. The same study shows why potency and efficacy are different numbers: in rat pituitary cells ipamorelin reached about 85% of GHRP-6's maximal growth hormone release, and GHRP-2 was more potent than ipamorelin in pigs but had a lower maximum. These are animal and cell results, so they describe the molecule, not what happens at any human dose.
How to read agonist data
- Find the receptor named in the source and note whether the data come from cells, animals or people.
- Look for the EC50 (potency: lower means less drug is needed) and the Emax (efficacy: the ceiling of the response).
- Compare the Emax with a reference full agonist. A clearly lower ceiling suggests partial agonism.
- Check what else the compound touches: other receptors, other hormones, off-target effects.
- Remember that receptor occupancy is not the same as response; cells can reach a full response with only part of their receptors occupied.
Fraction of receptors occupied = [drug] / ([drug] + Kd), where Kd is the concentration that occupies half the receptors.
At a drug concentration equal to Kd, occupancy is 1 / (1 + 1) = 50%. At 9 times Kd, occupancy is 9 / (9 + 1) = 90%. Going from 9 to 99 times Kd only moves occupancy from 90% to 99 / 100 = 99%, which is why piling on more drug quickly stops adding receptor activation.
Common mistakes
- Reading "agonist" as "strong": partial agonists are agonists too, with a lower ceiling.
- Confusing potency with efficacy: a lower EC50 does not mean a bigger maximal effect, as GHRP-2 versus ipamorelin shows.
- Assuming two agonists at the same receptor are interchangeable when their selectivity and side signals differ.
- Stacking two agonists for the same receptor and expecting their effects to add without limit; they compete for the same binding sites.
- Converting cell or animal potency numbers into a human dose.
Sources
- GuidelineInternational Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev, 2003. PMID 14657418.
- Preclinical studyIpamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998. PMID 9849822.
- ReviewMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab, 2018. PMID 29617641.
Page updated . How we grade evidence: methodology.
Related Terms
Receptor Antagonist
A receptor antagonist is a molecule that binds a receptor without activating it, blocking the body's own signal or a drug from switching it on.
GLP-1 Receptor
The GLP-1 receptor is the G protein-coupled receptor that GLP-1 activates to boost insulin, lower glucagon, slow the stomach and reduce appetite.
GIP Receptor
The GIP receptor is the receptor for GIP, a gut incretin hormone that boosts insulin after meals; tirzepatide activates it along with the GLP-1 receptor.
GLP-1 Agonist
A GLP-1 agonist is a drug that activates the receptor for glucagon-like peptide-1 (GLP-1), a gut hormone, and is used to lower blood glucose and body weight.
Look up any peptide term inside DoseCraft Pro
The glossary is just the start. Inside DoseCraft you get 90+ compound deep-dives, a PK-aware protocol engine, interaction checker, and vendor trust scores — every term surfaced in protocol-design context, not a separate page.
Start Free Trial